皮膚科 劉權毅醫師

1. Degos dz
2. atrophie blanche

Venous lakes are usually acquired venous lesions occurring on the face, neck and lips. These lesions commonly appear in people in their 40s or 50s and tend to become larger with time. They usually occur on sun-exposed parts of the lips, face and ears. They are also, commonly, benign growths.

Br J Dermatol. 2009 Nov;161(5):1081-8. Epub 2009 Jun 5.
Cytokine imbalance with increased production of interferon-alpha in psoriasiform eruptions associated with antitumour necrosis factor-alpha treatments.

Am J Clin Dermatol. 2008;9(1):1-14.
Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients.

28 October 2011

21 October 2011

Palmoplnatar punctate keratoses can be found in:
1. porokeratosis punctata palaris et plantaris

pancreaticoduodenectomy (Whipple)
short bowel syndrome

作者  中山醫學院內科 蔡嘉哲
文章網址

原文
http://dermatology.cdlib.org/143/commentary/alopecia/scheinfeld.html

http://www.dermquest.com/expert_opinions/surgery__cosmetics/botulinum_toxin_around_the_mouth.html

http://www.dermquest.com/expert_opinions/clinical_updates/facial_dermal_melanocytosis_common_misdiagnoses_.html
Dermal melanocytoses are usually localized and are especially common in Asians. Clinically, they all share a bluish-gray coloration. When a sufficient number of melanin-containing cells are present in the dermis, various clinical forms develop depending on their onset and distribution. Although most dermal melanocytoses are congenital or have an onset in early childhood, there is a group that is clearly acquired, with an onset in adult life. Mongolian spots typically disappear in childhood, whereas other dermal melanocytoses persist for life.

I. Congenital
Hartnup disease

Certolizumab pegol is a monoclonal antibody directed against tumor necrosis factor alpha. More precisely, it is a PEGylated Fab' fragment of a humanized TNF inhibitor monoclonal antibody

November 24, 2009 (San Diego, California) — A new fully human monoclonal antibody (MAb) against TNF, golimumab (CNTO148, Centocor/Schering-Plough), is close to entering the market. Results from a phase2 clinical trial of 172 patients with rheumatoid arthritis (RA) show encouraging safety and efficacy data, investigators reported at the 2005 ACR/ARHP Annual Scientific Meeting [ 1 ]. Phase 3 studies of RA, psoriatic arthritis, and ankylosing spondylitis are planned to start soon, the companies tell rheuma wire . Golimumab could be launched in 2007.
 

Atopic dermatitis (AD) is a chronic and relapsing inflammatory skin disease characterized by the predominant infiltration of TH2-type cells in lesional skin. Thymus and activation-regulated chemokine (TARC/CCL17) is a chemokine that attracts CC chemokine receptor 4–positive (CCR4+) or CCR8+ cells. Objective: The purpose of this study was to investigate the participation of TARC in AD. Methods: We measured serum TARC levels in 40 patients with AD, 20 healthy control subjects, and 20 patients with psoriasis. We also examined disease activity by using SCORAD score; serum soluble E-selectin, soluble IL-2 receptor, IgE, and GM-CSF levels; and eosinophil numbers in peripheral blood, as well as correlations between TARC levels and these factors. The positivity of CCR4 of CD4+CD45RO+ cells in PBMCs was examined by using FACS analysis. Immunohistochemical staining of TARC and GM-CSF was performed in the lesional skin of patients with AD. Results: The serum TARC levels of patients with AD were significantly higher than those of healthy control subjects and patients with psoriasis. The serum TARC levels significantly correlated with eosinophil number (r = 0.61), SCORAD score (r = 0.60), and serum soluble E-selectin levels (r = 0.58) and weakly correlated with serum soluble IL-2 receptor levels (r = 0.34) in patients with AD. The TARC levels of patients with AD decreased after the treatment in accordance with the improvement of clinical symptoms. The CCR4 positivity of CD4+CD45RO+ cells in PBMCs of patients with AD was also higher than that of healthy control subjects. Immunohistochemical staining revealed that TARC was positive in ke-ratinocytes in the epidermis and in vascular endothelial cells, T cells, and dendritic cells in the dermis. Conclusion: Serum TARC levels are associated with disease activity of AD, and TARC may play an important role in the pathogenesis of AD. (J Allergy Clin Immunol 2001;107:535-41.)

SCORAD is a clinical tool used to assess the extent and severity of eczema (SCORing Atopic Dermatitis). Dermatologists may use this tool before and after treatment to determine whether the treatment has been effective.

Area

To determine extent, the sites affected by eczema are shaded on a drawing of a body. The rule of 9 is used to calculate the affected area (A) as a percentage of the whole body.

1. Franceschetti-Jadassohn syndrome
2. dermatopathia pigmentosa reticularis

lupus pernios: a variant of sarcoidosis
chilblain lupus: a variant of CLE